JPS593447B2 - 持続性経口薬剤の製法 - Google Patents

持続性経口薬剤の製法

Info

Publication number
JPS593447B2
JPS593447B2 JP49082097A JP8209774A JPS593447B2 JP S593447 B2 JPS593447 B2 JP S593447B2 JP 49082097 A JP49082097 A JP 49082097A JP 8209774 A JP8209774 A JP 8209774A JP S593447 B2 JPS593447 B2 JP S593447B2
Authority
JP
Japan
Prior art keywords
weight
hours
active substance
component
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP49082097A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5040719A (enExample
Inventor
ベネデイクト ゲラルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of JPS5040719A publication Critical patent/JPS5040719A/ja
Publication of JPS593447B2 publication Critical patent/JPS593447B2/ja
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP49082097A 1973-07-17 1974-07-17 持続性経口薬剤の製法 Expired JPS593447B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2336218A DE2336218C3 (de) 1973-07-17 1973-07-17 Orale Arzneiform

Publications (2)

Publication Number Publication Date
JPS5040719A JPS5040719A (enExample) 1975-04-14
JPS593447B2 true JPS593447B2 (ja) 1984-01-24

Family

ID=5887126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP49082097A Expired JPS593447B2 (ja) 1973-07-17 1974-07-17 持続性経口薬剤の製法

Country Status (9)

Country Link
US (1) US4083949A (enExample)
JP (1) JPS593447B2 (enExample)
AT (1) AT342203B (enExample)
BE (1) BE817732A (enExample)
CH (1) CH595841A5 (enExample)
DE (1) DE2336218C3 (enExample)
FR (1) FR2237620B1 (enExample)
GB (1) GB1469133A (enExample)
NL (1) NL165651C (enExample)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377196A1 (fr) * 1977-01-13 1978-08-11 Lipha Composition medicamenteuse a usage oral
US4218433A (en) * 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
FR2397840B1 (enExample) * 1977-07-22 1981-03-20 Cherqui Jean
US4220153A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Controlled release delivery system
US4220152A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Delivery system
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
GB1584130A (en) * 1978-05-30 1981-02-04 Wyeth John & Brother Ltd Indole derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
SE426548B (sv) * 1978-12-05 1983-01-31 Haessle Ab Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
FR2454804B1 (fr) * 1979-04-26 1986-11-21 Sanofi Sa Medicament a base de dihydroergotoxine et son procede de preparation
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
EP0052075A1 (de) * 1980-11-12 1982-05-19 Ciba-Geigy Ag Körnige Arzneimittel-Retardform
EP0052076B1 (de) * 1980-11-12 1985-05-29 Ciba-Geigy Ag Schnellzerfallende Arzneimittel-Presslinge
FR2494112B1 (enExample) * 1980-11-19 1986-01-10 Laruelle Claude
DE3264867D1 (en) * 1981-04-27 1985-08-29 Haessle Ab New pharmaceutical preparation
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3278491D1 (en) * 1981-07-15 1988-06-23 Key Pharma Sustained release theophyline
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
JPS5867616A (ja) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd 腸溶性マイクロカプセル
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DE3214667C2 (de) * 1982-04-21 1985-07-18 Akzo Gmbh, 5600 Wuppertal Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
EP0111560A4 (en) * 1982-06-14 1987-02-03 Key Pharma Sustained release aspirin.
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
WO1984000295A1 (en) * 1982-07-09 1984-02-02 Key Pharma Sustained release quinidine dosage form
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
JPS60221078A (ja) * 1984-04-18 1985-11-05 Morinaga Milk Ind Co Ltd 有用微生物粉末の粒状製品およびその製造法
GB2159714B (en) * 1984-06-04 1988-05-05 Sterwin Ag Pharmaceutical composition of sparingly soluble medicament and method for its preparation
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629619A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
IE58246B1 (en) * 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US5069911A (en) * 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
DE3676235D1 (de) * 1985-06-04 1991-01-31 Teijin Ltd Arzneizubereitung mit verzoegerter wirkstoffabgabe.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
DE3610878A1 (de) * 1986-04-01 1987-10-08 Boehringer Ingelheim Kg Formlinge aus pellets
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
IT1197316B (it) * 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
IL84599A0 (en) * 1986-12-09 1988-04-29 Byk Gulden Lomberg Chem Fab Pharmaceutical composition containing urapidil and process for the preparation thereof
SE460946B (sv) * 1987-03-16 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av kinidinglukonat
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US4966770A (en) * 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DK0559702T3 (da) * 1990-11-27 1995-05-15 Byk Gulden Lomberg Chem Fab Urapidil-slow-release-præparat
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
EP0653935B1 (en) * 1992-08-05 2002-05-08 F.H. FAULDING & CO. LIMITED Pelletised pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
ZA977873B (en) * 1996-09-30 1998-04-23 Alza Corp Dosage form and method for administering drug.
CA2264852C (en) * 1996-09-30 2005-11-01 Alza Corporation Use of methylphenidate or a pharmaceutically acceptable salt thereof
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE69924735T2 (de) * 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
EP1207860B1 (en) 1999-09-02 2007-10-24 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
AU6815901A (en) * 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2449729C (en) * 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
AU2002366029B2 (en) * 2001-11-21 2008-01-31 Eisai R And D Management Co., Ltd. Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
KR20050119676A (ko) * 2003-03-31 2005-12-21 제노포트 인코포레이티드 가바 유사체의 프로드러그를 사용한 열성 홍조의 치료 또는예방
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
BRPI0413756A (pt) * 2003-08-20 2006-10-31 Xenoport Inc composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
NZ579515A (en) * 2003-09-17 2011-09-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
NZ549838A (en) * 2004-03-26 2010-04-30 Eisai R&D Man Co Ltd Coated controlled-release preparation containing a gastric acid secretion inhibitor
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
CA2582300A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
MX2007005306A (es) * 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
CN101163676A (zh) 2005-02-23 2008-04-16 普雷萨药品公司 用于治疗运动障碍及其它cns适应症的多巴胺转运蛋白抑制剂
WO2006091790A1 (en) * 2005-02-23 2006-08-31 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US7351740B2 (en) 2005-06-20 2008-04-01 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US20060293218A1 (en) * 2005-06-22 2006-12-28 Meythaler Jay M Salicylate therapeutic compound and process for controlled delivery thereof
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
CN101410094B (zh) * 2006-01-27 2013-04-17 阿普塔利斯制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
MX2008014794A (es) 2006-05-26 2009-04-08 Pharmacofore Inc Liberacion controlada de opioides fenolicos.
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US20080161393A1 (en) * 2006-12-08 2008-07-03 Barrett Ronald W Use of prodrugs of GABA analogs for treating disease
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
WO2010118362A1 (en) 2009-04-09 2010-10-14 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for inducing physiological hypertrophy
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
AU2016332071B2 (en) 2015-10-01 2019-04-18 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTIPLE SUBUNITY OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND ABUSE
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
GB887682A (en) * 1958-10-22 1962-01-24 Upjohn Co Improvements in or relating to medicinal coating compositions
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3282790A (en) * 1963-05-31 1966-11-01 Upjohn Co Enteric coated tablet
IL27218A (en) * 1966-01-17 1970-05-21 Aerojet General Co Reverse osmosis and membrane manufacture
US3567809A (en) * 1966-10-07 1971-03-02 Fuji Photo Film Co Ltd Method of varying the pore diameters of fine pores in cellulose acetate film
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3593855A (en) * 1969-05-13 1971-07-20 Westinghouse Electric Corp High flow porous reverse osmosis membranes containing lipids
US3648845A (en) * 1969-09-02 1972-03-14 Us Interior Thin film separation membranes and processes for making same
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
CA952431A (en) * 1970-09-28 1974-08-06 Frank M. Bardani Controlled release medicament
JPS5518694B2 (enExample) * 1973-04-02 1980-05-21

Also Published As

Publication number Publication date
NL7409597A (nl) 1975-01-21
JPS5040719A (enExample) 1975-04-14
AT342203B (de) 1978-03-28
DE2336218B2 (de) 1979-05-17
ATA593274A (de) 1977-07-15
NL165651B (nl) 1980-12-15
DE2336218A1 (de) 1975-02-06
DE2336218C3 (de) 1985-11-14
GB1469133A (en) 1977-03-30
FR2237620A1 (enExample) 1975-02-14
US4083949A (en) 1978-04-11
NL165651C (nl) 1981-05-15
FR2237620B1 (enExample) 1978-07-28
BE817732A (fr) 1975-01-17
CH595841A5 (enExample) 1978-02-28

Similar Documents

Publication Publication Date Title
JPS593447B2 (ja) 持続性経口薬剤の製法
KR920004094B1 (ko) 지효성 약제의 제조방법
CN101375869B (zh) 含银杏叶提取物缓/控释微丸组合物及其制备方法
JP4072597B2 (ja) 持続性製剤
CN100352432C (zh) 含有那格列奈的制剂
KR880002673B1 (ko) 진통 캡슐제와 그 제조방법
JP2005516020A (ja) ゼロ次持続放出剤形およびその製造方法
HU197839B (en) Process for producing metoprolol containing pharmaceutical compositions
JPH0735328B2 (ja) 複数回の放出を行なう製剤
WO2000009133A1 (fr) Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
GB2025227A (en) Pharmaceutical preparations in retard form
JPH072635B2 (ja) 新規医薬製剤およびその製造方法
IE862493L (en) Controlled release pharmaceutical preparations
NO175405B (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat med sakte frigivelse, som ikke er et injeksonsfluid
CN102961363B (zh) 氯化钾缓释胶囊
CN101732275B (zh) 一种单硝酸异山梨酯双层渗透泵控释片及其制备方法
JP2004507487A (ja) 腸疾患治療薬
CN112451531B (zh) 一种阿司匹林和利伐沙班复方制剂及其制备方法
CN117157079A (zh) 一种口服肠溶皮质类固醇的药物组合物
CN101125134B (zh) 盐酸坦洛新缓释胶囊及其制备方法
JP2024515678A (ja) 薬物特異的送達用カプセル及びその調製方法
CN1321642C (zh) 泮托拉唑钠肠溶微丸
CN111743876A (zh) 富马酸奥比特嗪肠溶微丸及其制备方法和用途
CN101099762B (zh) 珍菊降压缓释制剂
JPH0774166B2 (ja) 徐放性被覆薬剤の製造方法